Article Text

Download PDFPDF

Cutting edge methodology
P1-46 Diagnostic radiation exposure and breast cancer risk in BRCA1/2 mutation carriers in the gene-rad-risk study
  1. A Pijpe1,
  2. N Andrieu2,
  3. D Easton3,
  4. A Kesminiene4,
  5. E Cardis5,
  6. Genepso study group6,
  7. C Nogues6,
  8. Embrace study group3,
  9. S Peock3,
  10. D Frost3,
  11. Hebon study group1,
  12. P Manders7,
  13. I Thierry-Chef4,
  14. D Goldgar8,
  15. M Hauptmann1,
  16. M Rookus1,
  17. F van Leeuwen1
  1. 1Netherlands Cancer Institute, Amsterdam, The Netherlands
  2. 2Institut Curie, Paris, France
  3. 3University of Cambridge, Cambridge, UK
  4. 4IARC, Lyon, France
  5. 5CREAL, Barcelona, Spain
  6. 6Centre René Huguenin, Saint-Cloud, France
  7. 7Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
  8. 8University of Utah, School of Medicine, Salt Lake City, USA


Introduction BRCA1/2 mutation carriers might be more sensitive to ionising radiation due to impaired DNA repair mechanisms.

Methods A retrospective European collaborative cohort study (GENE-RAD-RISK) of 1993 female BRCA1/2 mutation carriers was performed using self-reported exposure to diagnostic radiation. Risk of breast cancer was estimated using a weighted Cox proportional hazards model with cumulative radiation exposure from diagnostic procedures as a time-dependent variable lagged by 5 years.

Results are not presented in the abstract due to a publication embargo.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.